17 december, 2022 10:28 COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022 Läs mer
19 oktober, 2022 17:00 The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States Läs mer
11 oktober, 2022 13:00 ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Läs mer
10 augusti, 2022 ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012 Läs mer
13 juni, 2022 iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022 Läs mer
4 juni, 2022 iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022 Läs mer
25 april, 2022 iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden Läs mer
21 april, 2022 The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU Läs mer